501 related articles for article (PubMed ID: 35790708)
21. RRM adjacent TARDBP mutations disrupt RNA binding and enhance TDP-43 proteinopathy.
Chen HJ; Topp SD; Hui HS; Zacco E; Katarya M; McLoughlin C; King A; Smith BN; Troakes C; Pastore A; Shaw CE
Brain; 2019 Dec; 142(12):3753-3770. PubMed ID: 31605140
[TBL] [Abstract][Full Text] [Related]
22. RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathy.
Necarsulmer JC; Simon JM; Evangelista BA; Chen Y; Tian X; Nafees S; Marquez AB; Jiang H; Wang P; Ajit D; Nikolova VD; Harper KM; Ezzell JA; Lin FC; Beltran AS; Moy SS; Cohen TJ
Elife; 2023 Oct; 12():. PubMed ID: 37819053
[TBL] [Abstract][Full Text] [Related]
23. A panel of TDP-43-regulated splicing events verifies loss of TDP-43 function in amyotrophic lateral sclerosis brain tissue.
Cao MC; Ryan B; Wu J; Curtis MA; Faull RLM; Dragunow M; Scotter EL
Neurobiol Dis; 2023 Sep; 185():106245. PubMed ID: 37527763
[TBL] [Abstract][Full Text] [Related]
24. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A.
Brown AL; Wilkins OG; Keuss MJ; Hill SE; Zanovello M; Lee WC; Bampton A; Lee FCY; Masino L; Qi YA; Bryce-Smith S; Gatt A; Hallegger M; Fagegaltier D; Phatnani H; ; Newcombe J; Gustavsson EK; Seddighi S; Reyes JF; Coon SL; Ramos D; Schiavo G; Fisher EMC; Raj T; Secrier M; Lashley T; Ule J; Buratti E; Humphrey J; Ward ME; Fratta P
Nature; 2022 Mar; 603(7899):131-137. PubMed ID: 35197628
[TBL] [Abstract][Full Text] [Related]
25.
Cook CN; Wu Y; Odeh HM; Gendron TF; Jansen-West K; Del Rosso G; Yue M; Jiang P; Gomes E; Tong J; Daughrity LM; Avendano NM; Castanedes-Casey M; Shao W; Oskarsson B; Tomassy GS; McCampbell A; Rigo F; Dickson DW; Shorter J; Zhang YJ; Petrucelli L
Sci Transl Med; 2020 Sep; 12(559):. PubMed ID: 32878979
[TBL] [Abstract][Full Text] [Related]
26. Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD.
Wood A; Gurfinkel Y; Polain N; Lamont W; Lyn Rea S
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946763
[TBL] [Abstract][Full Text] [Related]
27. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia.
Mackenzie IR; Rademakers R; Neumann M
Lancet Neurol; 2010 Oct; 9(10):995-1007. PubMed ID: 20864052
[TBL] [Abstract][Full Text] [Related]
28. Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy.
Khalil B; Chhangani D; Wren MC; Smith CL; Lee JH; Li X; Puttinger C; Tsai CW; Fortin G; Morderer D; Gao J; Liu F; Lim CK; Chen J; Chou CC; Croft CL; Gleixner AM; Donnelly CJ; Golde TE; Petrucelli L; Oskarsson B; Dickson DW; Zhang K; Shorter J; Yoshimura SH; Barmada SJ; Rincon-Limas DE; Rossoll W
Mol Neurodegener; 2022 Dec; 17(1):80. PubMed ID: 36482422
[TBL] [Abstract][Full Text] [Related]
29. Modelling TDP-43 proteinopathy in Drosophila uncovers shared and neuron-specific targets across ALS and FTD relevant circuits.
Godfrey RK; Alsop E; Bjork RT; Chauhan BS; Ruvalcaba HC; Antone J; Gittings LM; Michael AF; Williams C; Hala'ufia G; Blythe AD; Hall M; Sattler R; Van Keuren-Jensen K; Zarnescu DC
Acta Neuropathol Commun; 2023 Oct; 11(1):168. PubMed ID: 37864255
[TBL] [Abstract][Full Text] [Related]
30. Stathmin-2: adding another piece to the puzzle of TDP-43 proteinopathies and neurodegeneration.
Glass JD
J Clin Invest; 2020 Nov; 130(11):5677-5680. PubMed ID: 33074248
[TBL] [Abstract][Full Text] [Related]
31. TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis.
Palomo V; Tosat-Bitrian C; Nozal V; Nagaraj S; Martin-Requero A; Martinez A
ACS Chem Neurosci; 2019 Mar; 10(3):1183-1196. PubMed ID: 30785719
[TBL] [Abstract][Full Text] [Related]
32. RNA-binding proteins with prion-like domains in health and disease.
Harrison AF; Shorter J
Biochem J; 2017 Apr; 474(8):1417-1438. PubMed ID: 28389532
[TBL] [Abstract][Full Text] [Related]
33. ALS and FTD: Where RNA metabolism meets protein quality control.
Mandrioli J; Mediani L; Alberti S; Carra S
Semin Cell Dev Biol; 2020 Mar; 99():183-192. PubMed ID: 31254610
[TBL] [Abstract][Full Text] [Related]
34. Loss of Nuclear TDP-43 Is Associated with Decondensation of LINE Retrotransposons.
Liu EY; Russ J; Cali CP; Phan JM; Amlie-Wolf A; Lee EB
Cell Rep; 2019 Apr; 27(5):1409-1421.e6. PubMed ID: 31042469
[TBL] [Abstract][Full Text] [Related]
35. An amyloid-like cascade hypothesis for C9orf72 ALS/FTD.
Edbauer D; Haass C
Curr Opin Neurobiol; 2016 Feb; 36():99-106. PubMed ID: 26555807
[TBL] [Abstract][Full Text] [Related]
36. Cytoplasmic TDP-43 De-mixing Independent of Stress Granules Drives Inhibition of Nuclear Import, Loss of Nuclear TDP-43, and Cell Death.
Gasset-Rosa F; Lu S; Yu H; Chen C; Melamed Z; Guo L; Shorter J; Da Cruz S; Cleveland DW
Neuron; 2019 Apr; 102(2):339-357.e7. PubMed ID: 30853299
[TBL] [Abstract][Full Text] [Related]
37. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis.
Suk TR; Rousseaux MWC
Mol Neurodegener; 2020 Aug; 15(1):45. PubMed ID: 32799899
[TBL] [Abstract][Full Text] [Related]
38. Altered mRNP granule dynamics in FTLD pathogenesis.
Bowden HA; Dormann D
J Neurochem; 2016 Aug; 138 Suppl 1():112-33. PubMed ID: 26938019
[TBL] [Abstract][Full Text] [Related]
39. The emerging roles of microRNAs in the pathogenesis of frontotemporal dementia-amyotrophic lateral sclerosis (FTD-ALS) spectrum disorders.
Gascon E; Gao FB
J Neurogenet; 2014; 28(1-2):30-40. PubMed ID: 24506814
[TBL] [Abstract][Full Text] [Related]
40. Understanding In Vitro Pathways to Drug Discovery for TDP-43 Proteinopathies.
Cheng HWA; Callis TB; Montgomery AP; Danon JJ; Jorgensen WT; Ke YD; Ittner LM; Werry EL; Kassiou M
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
